본문 바로가기

Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
CLINICAL THERAPEUTICS40(1) · pp.83 · 2018
피인용
Web of Science 25Scopus 32
FWCI (Scopus)
1.38
JCR IF
JCR 2017 3.185
ISSN
0149-2918

저자

  1. Kim, Chee Hae제1저자Department of Internal Medicine, Seoul National University Hospital, Cardiovascular Centre, Seoul, South Korea
  2. Han, Kyung AhDiabetes Center, Eulji University, Seoul Eulji hospital, Seoul, South Korea
  3. Yu, JaemyungKangnam Sacred Heart Hospital, Seoul, South Korea
  4. Lee, Sang HakCardiology Division, Yonsei University College of Medicine, Severance Cardiovascular Hospital, Seoul, South Korea
  5. Jeon, Hui KyungDepartment of Internal Medicine, Division of Cardiology, The Catholic University of Korea, Seoul, South Korea
  6. Kim, Sang HyunDepartment of Cardiology, Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea
  7. Kim, Seok YeonDepartment of Internal Medicine, Seoul Medical Center, Seoul, South Korea
  8. Han, Ki HoonDepartments of Cardiology, Ischemic Heart Disease Center, Asan Medical Center Heart Institute, Seoul, South Korea
  9. Won, KyungheonDepartment of Internal Medicine, Seoul Medical Center, Seoul, South Korea
  10. Kim, Dong-BinDepartment of Cardiology, Catholic University of Korea College of Medicine, Seoul, South Korea
  11. Lee, Kwang-JaeDepartment of Endocrinology, Daedong Hospital, Seoul, South Korea
  12. Min, KyungwanDiabetes Center, Eulji University, Seoul Eulji hospital, Seoul, South Korea
  13. Byun, Dong WonEndocrinology and Metabolism, Soonchunhyang University Hospital, Seoul, South Korea
  14. Lim, Sang-WookDepartment of Cardiology, Bundang Cha General Hospital, Seoul, South Korea
  15. Ahn, Chul WooDepartment of Internal Medicine, Gangnam Severance Hospital, Seoul, South Korea
  16. Kim, SeongHwanDivision of Cardiology, Department of Medicine, Korea University Ansan Hospital, Seoul, South Korea
  17. Hong, Young JoonHeart Center of Chonnam National University Hospital, Chonnam National University, Seoul, South Korea
  18. Sung, JidongDivision of Cardiology, Cardiac and Vascular Center, Samsung Medical Center, Seoul, South Korea
  19. Hur, Seung-HoDepartment of Cardiology, Keimyung University Dongsan Hospital, Daegu, South Korea
  20. Hong, Soon JunKorea University Medical Center, Korea University, Seoul, South Korea
  21. Lim, Hong-SeokDepartment of Cardiology, Ajou University School of Medicine, Suwon, South Korea
  22. Park, Ie ByungDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea
  23. 김인주Department of Internal Medicine, Pusan National University College of Medicine, Busan, South Korea
  24. Lee, HyoungwooDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea
  25. Kim, Hyo-Soo교신저자Department of Internal Medicine, Seoul National University Hospital, Cardiovascular Centre, Seoul, South Korea

초록

Purpose: The purpose of this study was to examine the efficacy and safety of adding omega-3 fatty acids to rosuvastatin in patients with residual hypertriglyceridemia despite statin treatment. Methods: This study was a multicenter, randomized, double-blind, placebo-controlled study. After a 4-week run-in period of rosuvastatin treatment, the patients who had residual hypertriglyceridemia were randomized to receive rosuvastatin 20 mg/d plus omega-3 fatty acids 4 g/d (ROSUMEGA group) or rosuvastatin 20 mg/d (rosuvastatin group) with a 1:1 ratio and were prescribed each medication for 8 weeks. Findings: A total of 201 patients were analyzed (mean [SD] age, 58.1 [10.7] years; 62.7% male). After 8 weeks of treatment, the percentage change from baseline in triglycerides (TGs) and non-HDL-C was significantly greater in the ROSUMEGA group than in the rosuvastatin group (TGs: -26.3% vs -11.4%, P < 0.001; non-HDL-C: -10.7% vs -2.2%, P = 0.001). In the linear regression analysis, the lipid-lowering effect of omega-3 fatty acids was greater when baseline TG or non-HDL-C levels were high and body mass index was low. The incidence of adverse events was not significantly different between the 2 groups. (C) 2018 The Authors. Published by Elsevier HS Journals, Inc.

키워드

combinationhypertriglyceridemianon-HDL-Comega-3 fatty acidsrosuvastatintriglyceridesDENSITY-LIPOPROTEIN CHOLESTEROLCORONARY-HEART-DISEASEESTER AMR101 THERAPYNON-HDL CHOLESTEROLCARDIOVASCULAR-DISEASEEICOSAPENTAENOIC ACIDHIGH-RISKTRIGLYCERIDE LEVELSMETABOLIC SYNDROMEFATTY-ACIDS

식별자

Scopus EID
2-s2.0-85039991220
WoS UID
000423137800010